Skip to main content

Advertisement

SpringerLink
Log in

Urapidil, a dual-acting antihypertensive agent: Current usage considerations

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Despite the availability of a wide range of effective blood pressure (BP)-lowering agents, a substantial proportion of patients with hypertension fail to achieve target BP levels. The majority of patients with hypertension need a combination of two or more drugs to achieve BP targets and choice of second-line or subsequent-line therapy is an important consideration in hypertension management. Alpha-1-adrenoreceptor antagonists (alpha-blockers) have a BP-lowering effect broadly similar to the other antihypertensive drug classes and are effective as add-on therapy in patients with inadequately controlled hypertension. Alpha-blockers may also have therapeutic benefits that go beyond BP control, including improvements in lipid profile and glucose metabolism, as well as reducing the symptoms of benign prostatic hyperplasia. Urapidil has an alpha-blocking effect but, unlike other alpha-blockers, also has a central sympatholytic effect mediated via stimulation of serotonin 5HT1A receptors in the central nervous system. Several studies have suggested that oral urapidil is effective and well tolerated when used as second-line therapy in patients with BP inadequately controlled with other agents. Urapidil has also been shown to improve glucose and lipid metabolism in hypertensive patients with concomitant diabetes and/or hyperlipidemia. Intravenous urapidil is effective in the treatment of hypertensive crises, perioperative hypertension, and pre-eclampsia and may have a potential role in the management of acute stroke. In this review, the use of alpha-blockers in hypertension is discussed, with particular focus on urapidil for the lowering of BP in a variety of clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ezzati M, Lopez A, Rodgers A, Vander Hoorn S, Murray CJL, eds. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization; 2004.

    Google Scholar 

  2. Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361:878–887.

    Article  PubMed  CAS  Google Scholar 

  3. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–17.

    Article  PubMed  CAS  Google Scholar 

  4. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:536–544.

    Article  CAS  Google Scholar 

  5. Antikainen RL, Moltchanov VA, Chukwuma C Sr, et al. WHO MONICA Project. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA roject. Eur J Cardiovasc Prev Rehabil. 2006;13:13–29.

    Article  PubMed  Google Scholar 

  6. Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension. 2009;53:480–486.

    Article  PubMed  CAS  Google Scholar 

  7. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–1536.

    PubMed  Google Scholar 

  8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:(doi: 10.1136/bmj.b1665).

  9. De Bacquer D, De Backer G. The prevalence of concomitant hypertension and hypercholesterolaemia in the general population. Int J Hypertens. 2006;110:217–223.

    Google Scholar 

  10. Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2009;4:CD004643.

    PubMed  Google Scholar 

  11. Zusman RM. The role of alpha 1-blockers in combination therapy for hypertension. Int J Clin Pract. 2000;54:36–40.

    PubMed  CAS  Google Scholar 

  12. van Zwieten PA, Blauw GJ, van Brummelen P. Pharmacological profile of antihypertensive drugs with serotonin receptor and alpha-adrenoceptor activity. Drugs. 1990;40(suppl. 4):1–8.

    Article  PubMed  Google Scholar 

  13. Dooley M, Goa KL. Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998;56:929–955.

    Article  PubMed  CAS  Google Scholar 

  14. Zanchetti A. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group. Blood Press Suppl. 1995;3:38–46.

    PubMed  CAS  Google Scholar 

  15. Mizuno K, Fukuchi S. Antihypertensive effectiveness of urapidil alone and in combination with nifedipine in mild to moderate essential hypertension. Curr Ther Res. 1991;50:274–281.

    Google Scholar 

  16. Fariello R, Dal Palu C, Pessina A, et al. Antihypertensive efficacy of urapidil versus hydrochlorothiazide alone in patients with mild to moderate essential hypertension and of their combination in nonresponders to monotherapy. Drugs. 1990;40(suppl. 4):60–62.

    Article  PubMed  Google Scholar 

  17. Kaneko Y. Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension. Drugs. 1988;35(suppl. 6):156–163.

    Article  PubMed  Google Scholar 

  18. Takeda T, Kaneko Y, Shionoiri H, et al. Urapidil in patients with severe hypertension and in long-term treatment. J Hypertens Suppl. 1988;6:S37–42.

    PubMed  CAS  Google Scholar 

  19. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24:3–10.

    Article  PubMed  CAS  Google Scholar 

  20. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet. 2007;369:201–207.

    Article  PubMed  CAS  Google Scholar 

  21. Fariello R, Boni E, Corda L, Zaninelli A, Noseda A, Spinazzi A. Influence of a new multifactorial antihypertensive on blood pressure and metabolic profile in essential hypertension associated with non-insulin-dependent diabetes mellitus. Eur Heart J. 1992;13(suppl. A):65–69.

    Google Scholar 

  22. Oren S, Turkot S, Paran E, Flandra O, Slezak L, Hof B. Efficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). J Hum Hypertens. 1996;10:123–127.

    PubMed  CAS  Google Scholar 

  23. Goto Y. Effects of sustained-release urapidil on essential hypertension and hyperlipidaemia: a multicenter clinical trial. Curr Ther Res. 1992;51:870–876.

    Google Scholar 

  24. Ferrara LA, Leonetti G, Fogari R, Mazzola C, Mancini M, Zanchetti A. Urapidil in hypercholesterolemic hypertensive patients. Blood Press Suppl. 1994;4:39–44.

    PubMed  CAS  Google Scholar 

  25. Pattenier JW, von Heusinger FC. Effect of urapidil treatment on lipid metabolism in patients with hypertension. Royal Soc Med Int Congr Symp. 1992:196:61–67.

    Google Scholar 

  26. Gerber A, Weidmann P, Marone C, Uehlinger D, Riesen W. Cardiovascular and metabolic profile during intervention with urapidil in humans. Hypertension. 1985;7:963–971.

    PubMed  CAS  Google Scholar 

  27. Held K, Cremer P, Hundertmark E, Seidel D. Effects of long-term antihypertensive therapy with Urapidil (EbrantilR) on lipometabolism. Hochdruck. 1985;5:2.

    Google Scholar 

  28. Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil [in German]. Fortschr Med. 1988;106:651–654.

    PubMed  CAS  Google Scholar 

  29. Haenni A, Lithell H. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. Metabolism. 1996;45:1221–1229.

    Article  PubMed  CAS  Google Scholar 

  30. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956–963.

    PubMed  CAS  Google Scholar 

  31. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–1809.

    Article  PubMed  CAS  Google Scholar 

  32. Sebekova K, Fedelesova V, Blazicek P, Dzurik R. Acute effect of urapidil on peripheral serotonin metabolism. Cor Vasa. 1990;32:274–281.

    PubMed  CAS  Google Scholar 

  33. Smith CC, Betteridge DJ, Prichard BN. Platelet in vitro responses to urapidil and prazosin. Drugs. 1990;40(suppl. 4):48–51.

    Article  PubMed  CAS  Google Scholar 

  34. Storck J, Ochs JG, Kirsten R. Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets. Int J Clin Pharmacol Ther Toxicol. 1990;28:303–308.

    PubMed  CAS  Google Scholar 

  35. Kawabe K, Tsuchida S, Shimazaki J, Morita T, Yasuda K, Kageyama S. Effect on urapidil on benign prostatic hypertrophy: a multicenter, double-blind study. Urol Int. 1993;50:27–32.

    Article  PubMed  CAS  Google Scholar 

  36. Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder: a placebo controlled double-blind study. J Urol. 1996;156:1125–1130.

    Article  PubMed  CAS  Google Scholar 

  37. Yamanishi T, Yasuda K, Homma Y, Kawabe K, Morita T. A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction. Eur Urol. 1999;35:45–51.

    Article  PubMed  CAS  Google Scholar 

  38. Yamanishi T, Yasuda K, Kamai T, et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol. 2004;11:88–96.

    Article  PubMed  CAS  Google Scholar 

  39. Ikeda Y, Takagi N, Takeda K. Clinical evaluation of urapidil in hypertensive patients with renal failure. Shinyaku to Rinsho. 1992;41:622–631.

    Google Scholar 

  40. de Leeuw PW, van Es PN, de Bruyn HA, Birkenhäger WH. Renal haemodynamic and neurohumoral responses to urapidil in hypertensive man. Drugs. 1988;35(suppl. 6):74–77.

    Article  PubMed  Google Scholar 

  41. Lavrijssen AT, Kroon AA, Fuss-Lejeune M, Schiffers PM, de Leeuw PW. Renal haemodynamics and sodium excretory capacity during urapidil treatment in patients with essential hypertension. J Hypertens. 2000;18:963–969.

    Article  PubMed  CAS  Google Scholar 

  42. Liebau H, Wurst W, Harder I, Solleder P. Metabolically neutral therapy of hypertension. An open, multicenter, prospective long-term study of the tolerance, safety and effectiveness of urapidil. Fortschr Med. 1988;106:651–654.

    PubMed  CAS  Google Scholar 

  43. Liebau H, Solleder P, Harder I, Wurst W. Long-term antihypertensive therapy with urapidil. A 3-year open, multicenter trial of tolerance, safety and effectiveness. Fortschr Med. 1990;108:325–328.

    PubMed  CAS  Google Scholar 

  44. Haerlin R. Treatment of primary and secondary hypertension. Long-term use of urapidil (Ebrantil®). Clinical Trials J. 1985;22:215–225.

    Google Scholar 

  45. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med. 2002;17:937–945.

    Article  PubMed  Google Scholar 

  46. Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies. Cochrane Database Syst Rev. 2008;1:CD003653.

    PubMed  Google Scholar 

  47. Agence Française de Sécurité Sanitaire Des Produits de Santé (AFSSAPS). Poussees hypertensives de l’adulte: elevation tensionnelle sans souffrance viscerale immediate et urgences hypertensives [in French]. Agence Française de Sécurité Sanitaire Des Produits de Santé, Saint Denis, France, May 2002. Available at www.afssaps.fr/var/afssaps_site/storage/original/application/460262f69aa6b448962c08cba7d8be4f.pdf. Accessed May 24, 2010.

    Google Scholar 

  48. Slany J, Magometschnigg D, Mayer G, et al. Klassifikation, Diagnostik und Therapie der Hypertonie 2007 - Empfehlungen der Österreichischen Gesellschaft für Hypertensiologie [in German]. J Hypertonie. 2007;11:7–11.

    Google Scholar 

  49. Zähringer J, Klepzig M, Greif J, Ludwig B, Strauer B. Therapy of the hypertensive crisis with urapidil. Various effects on patients with or without coronary disease. Fortschr Med. 1984;102:624–628.

    PubMed  Google Scholar 

  50. Błaszyk K, Grajek S, Skorupski W, et al. Evaluation of the antihypertensive efficacy of urapidil in the treatment of hypertension emergencies [in Polish]. Pol Arch Med Wewn. 1995;94:512–517.

    PubMed  Google Scholar 

  51. Alijotas-Reig J, Bove-Farre I, de Cabo-Frances F, Angles-Coll R. Effectiveness and safety of prehospital urapidil for hypertensive emergencies. Am J Emerg Med. 2001;19:130–133.

    Article  PubMed  CAS  Google Scholar 

  52. Jelakovic B, Grba-Bujevic M, Bosan-Kilibarda I, et al. Hypertensive crisis. Efficacy and safe of urapidil based protocol in out-of-hospital settings. J Hypertens. 2009;27(suppl. 4):S122, P11.305.

    Google Scholar 

  53. Hirschl MM, Seidler D, Zeiner A, et al. Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive urgencies. Am J Emerg Med. 1993;11:653–656.

    Article  PubMed  CAS  Google Scholar 

  54. Hirschl MM, Seidler D, Müllner M, et al. Efficacy of different antihypertensive drugs in the emergency department. J Hum Hypertens. 1996;10(suppl. 3):S143–146.

    PubMed  Google Scholar 

  55. Hirschl MM, Binder M, Bur A, et al. Safety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergencies. Intensive Care Med. 1997;23:885–888.

    Article  PubMed  CAS  Google Scholar 

  56. Woisetschläger C, Bur A, Vlcek M, Derhaschnig U, Laggner AN, Hirschl MM. Comparison of intravenous urapidil and oral captopril in patients with hypertensive urgencies. J Hum Hypertens. 2006;20:707–709.

    Article  PubMed  CAS  Google Scholar 

  57. Späh F, Grosser KD, Thieme G. Acute haemodynamic effects of urapidil and nifedipine in hypertensive urgencies and emergencies. Drugs. 1990;40(suppl. 4):58–59.

    Article  PubMed  Google Scholar 

  58. Wacker J, Werner P, Walter-Sack I, Bastert G. Treatment of hypertension in patients with preeclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. Nephrol Dial Transplant. 1998;13:318–325.

    Article  PubMed  CAS  Google Scholar 

  59. Wacker JR, Wagner BK, Briese V, et al. Antihypertensive therapy in patients with preeclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. Eur J Obstet Gynecol Reprod Biol. 2006;127:160–165.

    Article  PubMed  CAS  Google Scholar 

  60. Schulz M, Wacker J, Bastert G. Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns [in German]. Zentralbl Gynakol. 2001;123:529–533.

    Article  PubMed  CAS  Google Scholar 

  61. Deutsche Hochdruckliga e.V. DHLR - Deutsche Hypertonie Gesellschaft. Leitlinien zur behandlung der arteriellen hypertonie. Heidelberg, Germany, 2008. Available at: www.hochdruckliga.de. Accessed: May 24, 2010.

  62. Olmos M, Vidarte MA, Ballester JA, Lasuen J, Escobar A. Efficacy of a single dose of urapidil for preventing arterial hypertension during the pre-bypass period in coronary surgery. Rev Esp Anestesiol Reanim. 2000;47:337–342.

    PubMed  CAS  Google Scholar 

  63. Gob E, Barankay A, Richter JA. Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine. Arzneimittelforschung. 1981;31:1479–1481.

    PubMed  CAS  Google Scholar 

  64. Hess W. Urapidil versus clonidine. Acute haemodynamic effects during control of intraoperative hypertensive episodes. Drugs. 1990;40(suppl. 4):77–79.

    Article  PubMed  Google Scholar 

  65. Hess W, Schulte-Sasse U, Tarnow J, Veit S. Comparison of phentolamine and urapidil in controlling acute intra-operative hypertension in patients subjected to coronary artery bypass surgery. Eur J Anaesthesiol. 1985;2:21–27.

    PubMed  CAS  Google Scholar 

  66. Petry A, Wulf H, Baumgartel M. The influence of ketanserin or urapidil on haemodynamics, stress response and kidney function during operations for myocardial revascularisation. Anaesthesia. 1995;50:312–316.

    Article  PubMed  CAS  Google Scholar 

  67. van der Stroom JG, Van Wezel HB, Koolen JJ, Visser CA, Van Zwieten PA. Comparison of the effects of urapidil and nitroprusside on hemodynamics and myocardial function in hypertension following cardiac surgery. Blood Press Suppl. 1994;4:31–38.

    PubMed  Google Scholar 

  68. van der Stroom JG, van Wezel HB, Langemeijer JJ, et al. A randomized multicenter double-blind comparison of urapidil and ketanserin in hypertensive patients after coronary artery surgery. J Cardiothorac Vasc Anesth. 1997;11:729–736.

    Article  PubMed  Google Scholar 

  69. van der Stroom JG, van Wezel HB, Vergroesen I, et al. Comparison of the effects of urapidil and sodium nitroprusside on haemodynamic state, myocardial metabolism and function in patients during coronary artery surgery. Br J Anaesth. 1996;76:645–651.

    PubMed  Google Scholar 

  70. Mollhoff T, Van Aken H, Mulier JP, Muller E, Lauwers P. Effects of urapidil, ketanserin and sodium nitroprusside on venous admixture and arterial oxygenation following coronary artery bypass grafting. Br J Anaesth. 1990;64:493–497.

    Article  PubMed  CAS  Google Scholar 

  71. van Hemelrijck J, Waets P, Aken H van, Lacroix H, Nevelsteen A, Suy R. Blood pressure management during aortic surgery - Urapidil compared to isosorbide dinitrate. J Cardiothorac Vasc Anesth. 1993;7:273–278.

    Article  PubMed  Google Scholar 

  72. Zander J, Puchstein C, Aken H van, Lawin P. Urapidil as a supplement to neuroleptanalgesia during neuroanaesthesia. Br J Anaesth. 1984;56:1304–1305.

    Google Scholar 

  73. Puchstein C, Van Aken H, Zander J, Lawin P. The use of urapidil in the postoperative period. Anaesthesist. 1984;33:224–227.

    PubMed  CAS  Google Scholar 

  74. Gosse P, Tauzin-Fin P, Sesay MB, Sautereau A, Ballanger P. Preparation for surgery of phaeochromocytoma by blockade of alpha-adrenergic receptors with urapidil: what dose? J Hum Hypertens. 2009;23:605–609.

    Article  PubMed  CAS  Google Scholar 

  75. Spah F, Walsemann SO. Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Blood Press Suppl. 1995;3:62–67.

    PubMed  CAS  Google Scholar 

  76. Wusten R, Hemelrijck J, Mattheussen M, Lauvers T, Anger C, van Aken H. Der einfluss von nifidepin und urapidil auf die autoregulation der zerebralen durchbtuling in gegenwart einer intrakraniellen raumforderung [in German]. Anasth Intensivther Notfallmed. 1990;25:140–145.

    Article  PubMed  CAS  Google Scholar 

  77. Prehn JH, Backhauss C, Karkoutly C, et al. Neuroprotective properties of 5-HT1A receptor agonists in rodent models of focal and global cerebral ischemia. Eur J Pharmacol. 1991;203:213–222.

    Article  PubMed  CAS  Google Scholar 

  78. European Stroke Initiative Executive Committee. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis. 2003;16:311–337.

    Article  Google Scholar 

  79. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7:391–399.

    Article  PubMed  Google Scholar 

  80. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–1975.

    Article  Google Scholar 

  81. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Diuretics versus alpha blockers as first-step antihypertensive therapy. Hypertension. 2003;42:239–246.

    Article  CAS  Google Scholar 

  82. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252.

    Article  PubMed  CAS  Google Scholar 

  83. Chapman N, Chang CL, Dahlöf B, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118:42–48.

    Article  PubMed  CAS  Google Scholar 

  84. Spoladore R, Roccaforte R, Fragasso G, et al. Safety and efficacy of doxazosin as “add-on” antihypertensive therapy in mild to moderate heart failure patients. Acta Cardiol. 2009;64:485–491.

    Article  PubMed  Google Scholar 

  85. Belz GG, Matthews JH, Graf D, et al. Dynamic responses to intravenous urapidil and dihydralazine in normal subjects. Clin Pharmacol Ther. 1985;37:48–54.

    PubMed  CAS  Google Scholar 

  86. Kobrin I, Amodeo C, Ventura HO, Messerli FH, Frohlich ED. Immediate hemodynamic effects of urapidil in patients with essential hypertension. Am J Cardiol. 1985:722–725.

  87. Stoschitzky K, Stoschitzky G, Wonisch M, Brussee H. Differential effects of urapidil and doxazosin on heart rate. Eur J Clin Pharmacol. 2007;63:259–262.

    Article  PubMed  CAS  Google Scholar 

  88. Hansson L, Petitet A. Review of studies with urapidil in elderly hypertensives. Blood Press Suppl. 1995;3:21–25.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ceresvej 10, 1863, Frederiksberg C, Denmark

    Jan Buch

Authors
  1. Jan Buch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Buch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buch, J. Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Therapy 27, 426–443 (2010). https://doi.org/10.1007/s12325-010-0039-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0039-0

Keywords

Search

Navigation